Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.38 USD
-0.12 (-8.00%)
Updated May 29, 2024 04:00 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
Nektar Therapeutics [NKTR]
Reports for Purchase
Showing records 141 - 160 ( 394 total )
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Our Thoughts Post Investor Dinner Event With NSCLC KOL
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Pre-ASH Catalyst Calendar For Stocks Under Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
We are dropping coverage of NKTR shares to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Clinical Updates Limited to Melanoma During the Remainder of 2018; Remain on the Sidelines Pending Clarity on NSCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
NKTR-181 Well on Its Way, But it is NKTR-214 We Are Less Sanguine About
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Confidence Shaken; Swallowing Our Lump of Coal and Moving to the Sidelines With a $54 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Giving NKTR-214 a Benefit of Doubt; but Mr. Market May Not Be as Forgiving; Adjusting PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
An FDA Alert on Peers Might Have Positive Ramifications for NKTR-214
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
ASCO Abstract; Durable Responses and Robust Activity in PD-L1 <1%, Without a Significant Increase in irAE''s
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
ASCO Expectations Potentially Reset; Pullbacks Could Get Compelling
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Estimates Update Ahead of 1Q18 Print; Focus Remains on ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
NKTR-214 Now More Consequential to Bristol-Myers as Frontline NSCLC Hurdle Gets Raised by Merck
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D